INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
The company's breast cancer screen test has also demonstrated superior accuracy over current tests.
Copyright 2024 – Finance News Network
06 Sep 2023 - Daniel Ortisi, Equity Research Analyst at Stock Doctor, discusses the winners and losers from reporting season and gives advice on portfolio positioning for FY24.
13 Feb 2020 - Centuria Capital Group (ASX:CNI) Joint CEO, John McBain talks 1H20 results & outlook, including the contribution from recent acquisitions as group AUM now exceeds $7.3B.
29 Jan 2021 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its recent cap raising to support rapid USA commercialisation for Technegas following USFDA approval targeted in Q2 2021.
29 Feb 2024 - Greg Miles - Managing Director - Caspin Resources Limited (ASX Code: CPN) is a new mineral exploration company based in Perth, Western Australia. Caspin has extensive skills and experience in early stage exploration and development. The Company is actively exploring the Yarawindah Brook Project in Australia’s exciting new PGE-Ni-Cu West Yilgarn province and the Mount Squires Project in the West Musgrave region, one of Australia’s last mineral exploration frontiers.
29 Sep 2023 - Vital Metals Limited (ASX:VML) Interim Non-Executive Chairman Richard Crookes discusses termination of the company's Saskatoon facility, the Tardiff rare earths asset, and next steps for the company.
01 Mar 2022 - IVE Group Limited (ASX:IGL) Executive Chairman Geoff Selig discusses the highlights of the company's recently released results, key drivers and outlook.
14 Oct 2024 - Weebit Nano Limited (ASX:WBT) Chairman Dadi Perlmutter discusses the company's innovative ReRAM technology as a superior alternative to flash memory. ReRAM has huge market potential, usable in devices from cars to smartphones.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.